In patients undergoing matched donor T deplete transplantation using anti-thymocyte globulin or alemtuzumab, a biomarker panel including HGF, elafin, sIL-2Rα, sTNFR1, and REG3α was predictive of GVHD and its severity (51). The gene discussed is REG3A; the disease is graft versus host disease.